{"id":"zoledronic-acid-i-v-2-years","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Renal impairment"},{"rate":"10-20%","effect":"Hypocalcemia"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Fever"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Bone pain"},{"rate":"5-10%","effect":"Musculoskeletal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bisphosphonates like zoledronic acid bind to hydroxyapatite in bone, inhibiting osteoclast-mediated bone resorption. This leads to a decrease in bone turnover and an increase in bone mineral density.","oneSentence":"Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:25.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of hypercalcemia of malignancy"},{"name":"Treatment of bone metastases in patients with advanced malignancies"},{"name":"Treatment of osteoporosis in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT00439647","phase":"PHASE3","title":"Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Male Osteoporosis","enrollment":1199},{"nctId":"NCT00132808","phase":"PHASE3","title":"Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-07","conditions":"Osteopenia","enrollment":581},{"nctId":"NCT01522521","phase":"PHASE3","title":"Study of AK156 in Primary Osteoporosis Patients","status":"COMPLETED","sponsor":"Asahi Kasei Pharma Corporation","startDate":"2012-02","conditions":"Osteoporosis","enrollment":600},{"nctId":"NCT02181101","phase":"PHASE3","title":"Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2005-09","conditions":"Breast Neoplasms","enrollment":3754},{"nctId":"NCT00762346","phase":"PHASE4","title":"Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2008-09","conditions":"Non Small Cell Lung Cancer, Bone Metastases, High NTX Level","enrollment":156},{"nctId":"NCT00375427","phase":"PHASE3","title":"Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-02","conditions":"Breast Cancer With Bone Metastasis","enrollment":430},{"nctId":"NCT01341262","phase":"PHASE2","title":"THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2002-03","conditions":"Multiple Myeloma","enrollment":378},{"nctId":"NCT00439244","phase":"PHASE3","title":"Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Osteoporosis","enrollment":412}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Zoledronic acid i.v. 2 years","genericName":"Zoledronic acid i.v. 2 years","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate. Used for Treatment of hypercalcemia of malignancy, Treatment of bone metastases in patients with advanced malignancies, Treatment of osteoporosis in postmenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}